Related Experiment Video
Updated: Mar 8, 2026

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
Published on: April 11, 2016
Tissue-based next generation sequencing: application in a universal healthcare system
Seán O Hynes1, Brendan Pang2,3, Jacqueline A James1,4
1Northern Ireland Molecular Pathology Laboratory, Centre for Cancer Research and Cell Biology, Queen's University Belfast, Belfast, Northern Ireland, UK.
Abstract:
In the context of solid tumours, the evolution of cancer therapies to more targeted and nuanced approaches has led to the impetus for personalised medicine. The targets for these therapies are largely based on the driving genetic mutations of the tumours. To track these multiple driving mutations the use of next generation sequencing (NGS) coupled with a morphomolecular approach to tumours, has the potential to deliver on the promises of personalised medicine. A review of NGS and its application in a universal healthcare (UHC) setting is undertaken as the technology has a wide appeal and utility in diagnostic, clinical trial and research paradigms. Furthermore, we suggest that these can be accommodated with a unified integromic approach. Challenges remain in bringing NGS to routine clinical use and these include validation, handling of the large amounts of information flow and production of a clinically useful report. These challenges are particularly acute in the setting of UHC where tests are not reimbursed and there are finite resources available. It is our opinion that the challenges faced in applying NGS in a UHC setting are surmountable and we outline our approach for its routine application in diagnostic, clinical trial and research paradigms.
Insights
Next-generation sequencing (NGS) advances personalized medicine for solid tumors by tracking genetic mutations. Integrating NGS into universal healthcare settings is feasible despite resource challenges.
Area of Science:
- Oncology
- Genomics
- Personalized Medicine
Background:
- Cancer therapies are evolving towards personalized medicine, targeting specific genetic mutations in solid tumors.
- Next-generation sequencing (NGS) is crucial for identifying and tracking multiple driving mutations.
- A morphomolecular approach combined with NGS offers potential for personalized cancer treatment.
Purpose of the Study:
- To review the application of NGS in a universal healthcare (UHC) setting.
- To explore the integration of NGS into diagnostic, clinical trial, and research paradigms.
- To propose a unified integromic approach for managing complex genomic data.
Main Methods:
- Review of existing literature on NGS technology and its clinical applications.
- Analysis of challenges in implementing NGS in routine clinical practice, particularly within UHC systems.
- Development of strategies for overcoming barriers such as validation, data handling, and reporting.
Main Results:
- NGS holds significant potential for personalized medicine in solid tumors.
- Challenges in NGS implementation include data management, reporting, and resource limitations in UHC.
- A unified integromic approach can streamline the use of NGS data.
Conclusions:
- The challenges of applying NGS in UHC settings are surmountable.
- Routine application of NGS is feasible across diagnostic, clinical trial, and research settings.
- Further development is needed to optimize NGS workflows for UHC environments.
More Related Videos
Related Concept Videos
Next-generation Sequencing
Next-Generation Sequencing Methods
Although all next-generation methods use different technologies, they all share a set of standard features....
Issues And Trends In Healthcare Delivery System
Cost Containment
Payment for healthcare services has historically promoted adoption of costly and often unnecessary or inefficient...
RNA-seq
Before the discovery of RNA-seq, microarray-based methods and Sanger sequencing were used for transcriptome analysis. However, while...
Secondary Healthcare System
Integrated Healthcare System
Tertiary Healthcare System

